Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Gounant

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2011
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)T C Gauler, B Besse, A Mauguen, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2025
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci studyM Wislez, C Mascaux, J Cadranel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 9, 2012
From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF)S Couraud, A B Cortot, L Greillier, et al.
Revue Des Maladies Respiratoires|January 28, 2014
[Individual lung cancer screening in practice. Perspectives on the propositions from the multidisciplinary group of the Intergroupe francophone de cancérologie thoracique, the Société d'imagerie thoracique and the Groupe d'oncologie de langue française]N Girard, V Gounant, B Mennecier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 14, 2026
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trialG Zalcman, A Madroszyk, E Guenzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2019
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryJ Mazieres, A Drilon, A Lusque, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2011
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)T C Gauler, B Besse, A Mauguen, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2025
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci studyM Wislez, C Mascaux, J Cadranel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 9, 2012
From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF)S Couraud, A B Cortot, L Greillier, et al.
Revue Des Maladies Respiratoires|January 28, 2014
[Individual lung cancer screening in practice. Perspectives on the propositions from the multidisciplinary group of the Intergroupe francophone de cancérologie thoracique, the Société d'imagerie thoracique and the Groupe d'oncologie de langue française]N Girard, V Gounant, B Mennecier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 14, 2026
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trialG Zalcman, A Madroszyk, E Guenzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2019
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryJ Mazieres, A Drilon, A Lusque, et al.
Pageof 6